てんかん誘発性神経変性とその治療的介入
Samar Kaddoura1, Anjali Banerjee2, Latha Ganti3,4
1Biology, Montverde Academy, Montverde, USA.
Cureus
|January 7, 2026
まとめ
本研究は、てんかんと神経変性に関する研究を分析し、発作や酸化ストレスなどの重要用語を特定する。研究の増加は、てんかん患者における神経損傷を防ぐまたは逆転させる可能性のある治療法の可能性を示唆している。
科学分野:
- 神経学
- 神経科学
- 生物医学研究
背景:
- てんかんは再発性の発作を特徴とし、神経変性と関連しています。
- てんかんと神経損傷の関係を理解することは、患者の転帰にとって重要です。
- 既存の研究では、発作活動と進行性の脳損傷との関連性が強調されています。
研究 の 目的:
- てんかん誘発性神経変性に関する科学出版物の書誌計量学的分析を実施すること。
- この分野における研究動向、主要な貢献者、および新たなテーマを特定すること。
- てんかんにおける神経損傷の潜在的な治療的介入を探求すること。
主な方法:
- Web of Scienceデータベースからの出版物の書誌計量学的分析。
- 1989年から2025年までの期間を対象としたデータ収集。
- 主要な用語、引用パターン、および研究成果の特定と分析。
主要な成果:
- 計662件の出版物を特定しました。
- 主要な用語には、発作、海馬、てんかん原性、酸化ストレスが含まれます。
- 近年、研究活動が著しく増加しています。
結論:
- てんかん誘発性神経変性の分野は急速に拡大しています。
- 新たな研究は、治療法開発のための有望な道筋を示唆しています。
- てんかん患者における神経変性を予防または逆転させる可能性が高まっています。
関連する概念動画
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Glutamate Antagonists
884
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
884
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
806
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
806
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


